How government health insurance coverage of novel anti-cancer medicines benefited patients in China – a retrospective analysis of hospital clinical data
Abstract Background China started to cover novel medicines for the treatment of major cancers, such as trastuzumab for breast cancer by the government health insurance programs since 2016. Limited data have been published on the use of cancer medications and little is known about how government heal...
Main Authors: | Yifan Diao, Mengbo Lin, Kai Xu, Ji Huang, Xiongwei Wu, Mingshuang Li, Jing Sun, Hong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12913-021-06840-3 |
Similar Items
-
Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study
by: Wenqing Fang, et al.
Published: (2021-08-01) -
Disability insurance benefit application in Switzerland: an analysis of linked administrative and survey data
by: Szilvia Altwicker-Hámori
Published: (2021-09-01) -
Economic Assessment and Community Management of <i>Prosopis juliflora</i> Invasion in Sweimeh Village, Jordan
by: Amani Al-Assaf, et al.
Published: (2020-10-01) -
ANALYSIS OF THE BENEFITS OF THE VOLUNTEER IN ROMANIA
by: Simona-Andreea APOSTU
Published: (2017-06-01) -
Does capitation prepayment based Integrated County Healthcare Consortium affect inpatient distribution and benefits in Anhui Province, China? An interrupted time series analysis
by: Dai Su, et al.
Published: (2019-07-01)